ENTRIES TAGGED "FDA"
Oliver Medvedik on the grassroots future of biohacking and the problems with government overreach.
Whither thou goest, synthetic biology? First, let’s put aside the dystopian scenarios of nasty modified viruses escaping from the fermentor Junior has jury-rigged in his bedroom lab. Designing virulent microbes is well beyond the expertise and budgets of homegrown biocoders.
“Moreover, it’s extremely difficult to ‘improve’ on the lethality of nature,” says Oliver Medvedik, a visiting assistant professor at The Cooper Union for the Advancement of Science and Art and the assistant director of the Maurice Kanbar Center for Biomedical Engineering. “The pathogens that already exist are more legitimate cause for worry.” Read more…
A backchannel look at what's on our radar.
The Radar team does a lot of sharing in the backchannel. Here’s a look at a selection of stories and innovative people and companies from around the web that have caught our recent attention. Have an interesting tidbit to contribute to the conversation? Send me an email or ping me on Twitter
- The edges of connected realities — Steve Mason’s TEDxSF talk, in which he discusses the evolution of connected environments and quotes Yves Behar: “The interface of the future is invisible.” (Jenn Webb, via Jim Stogdill, via Rachel Kalmar) Mason’s talk is a must-watch, so I’ll just provide direct access:
We must go beyond hype for incentives to provide data to researchers
The FDA order stopping 23andM3 from offering its genetic test kit strikes right into the heart of the major issue in health care reform: the tension between individual care and collective benefit. Health is not an individual matter. As I will show, we need each other. And beyond narrow regulatory questions, the 23andMe issue opens up the whole goal of information sharing and the funding of health care reform.
There have never been better reasons for doing right by ourselves
A few existing and upcoming projects that illustrate what games are doing in health care, and some trends to watch.
Can open data dominate biological science as open source has in software?
To move from a hothouse environment of experimentation to the mainstream of one of the world's most lucrative and tradition-bound industries, Sage Bionetworks must aim for its nucleus: rewards and incentives. Comparisons to open source software and a summary of tasks for Sage Congress.
The Vioxx problem is just one instance of the wider malaise afflicting the drug industry. Managers from major pharma companies expressed confidence that they could expand public or "pre-competitive" research in the direction Sage Congress proposed. The sector left to engage is the one that's central to all this work–the public.
Connecting medical devices to electronic health record systems, and the roles of open source software, regulation, and clinical improvement.